Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 91 clinical trials
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+ HER2+ Advanced Breast Cancer Patients

(NCCN 2018). Recently, various CDK4/6 inhibitors including palbociclib, abemaciclib, and ribociclib were approved by FDA based on the clinical trial results demonstrating prolonged PFS over ET

breast cancer
oophorectomy
ribociclib
endocrine therapy
her2/neu-positive breast cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
AKT Inhibitor Ipatasertib With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

This research is looking to find out if the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant can be an effective treatment for breast cancer.

mammogram
endocrine therapy
fulvestrant
palbociclib
aromatase inhibitor
  • 6 views
  • 25 Jan, 2021
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)

  • 84 views
  • 26 Feb, 2021
  • 17 locations
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+) Her2(-) Metastatic Breast Cancer

The study is designed to compare the clinical benefit following treatment with aromatase inhibitor in combination with metronomic capecitabine versus aromatase inhibitor alone in women with hormone receptor-positive, Her2-negative advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced/metastatic disease.

metastasis
capecitabine
anastrozole
letrozole
gonadotropin releasing hormone
  • 0 views
  • 21 Jan, 2021
  • 1 location
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

Despite different clinical characteristics including the response to treatment and the patterns of metastatic relapse, invasive lobular breast carcinoma (ILBC) is treated like invasive ductal breast carcinoma (IDBC) carcinoma both in the clinics and in clinical trials. A large majority of ILBC are ER+/HER2- and almost 90% have loss of …

  • 0 views
  • 02 Mar, 2021
  • 6 locations
Palbociclib in Real World Practice

This Non-Interventional Study will describe and analyze the clinical use of palbociclib in routine clinical practice in the treatment of advanced breast cancer.

breast cancer
adenocarcinoma
metastasis
advanced breast cancer
breast adenocarcinoma
  • 2226 views
  • 29 Jan, 2021
  • 299 locations
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

The purpose of this study is to evaluate efficacy and safety of CDK4/6 inhibitor Palbociclib in combination with Fulvestrant versus Fulvestrant in female patients with HR+/HER2- advanced breast

metastasis
tumor cells
mammogram
endocrine therapy
tamoxifen
  • 0 views
  • 24 Jan, 2021
  • 1 location
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

This is a prospective, single-arm, multi-center observational non-interventional study (NIS) in Germany and Austria.

  • 0 views
  • 28 Feb, 2021
  • 1 location
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

This is a multi-center, observational study designed to explore the regulatory mechanism of palbociclib correlative pathways in therapeutic process of breast cancer, employing next generation

metastasis
mammogram
endocrine therapy
hormone therapy
fulvestrant
  • 0 views
  • 24 Jan, 2021
  • 1 location
Pilot Study Assessing the Effect of Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in Patients With ER+/HER2- Metastatic Breast Cancer

The goal of this study is to evaluate changes in body composition among patients who are treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or palbociclib).

bisphosphonate
erbb2
breast adenocarcinoma
HER2
palbociclib
  • 2 views
  • 29 Jan, 2021
  • 1 location